Why a weaker stream, an enlarged prostate, and a rising PSA are different clinical questions.
If you already get up at night to urinate, or your stream has become weaker, it is reasonable to ask whether starting testosterone will make the problem worse. The prostate responds to androgens, so the concern has a biological basis. But the chain of events often presented to men—more testosterone, a larger prostate, more obstruction, worse urination—is much less predictable than it sounds.
In men with confirmed testosterone deficiency and without severe urinary symptoms at baseline, randomized trials have generally found no worsening of average urinary symptom scores with testosterone replacement. That is useful reassurance for appropriately selected patients. It does not establish safety in every man, settle the consequences of decades of treatment, or show that testosterone should be prescribed to treat an enlarged prostate. 1,2,3
To apply the research to your own situation, start with a more specific question: Are we trying to explain symptoms, measure obstruction, monitor prostate growth, or evaluate cancer risk? Those questions overlap, but they require different evidence.
Is the problem actually your prostate?
Lower urinary tract symptoms, abbreviated LUTS, include several experiences that men often group together:
- Storage symptoms: urgency, frequent urination, and waking from sleep to urinate, called nocturia.
- Voiding symptoms: difficulty starting, a weak or interrupted stream, and straining.
- Post-void symptoms: a feeling of incomplete emptying or dribbling after finishing.
Benign prostatic hyperplasia, or BPH, is noncancerous growth of prostate tissue. It can enlarge the gland and obstruct the urethra, the channel carrying urine out of the bladder. However, the size of the gland does not tell you how severely a man is obstructed or how much his symptoms bother him. Bladder function, prostate shape, and muscle tone around the outlet also contribute. 1,4
Think about what has to happen during urination. The bladder wall must contract effectively while the outlet allows urine to pass. A weak stream can reflect excessive outlet resistance, an underactive bladder, or both. Conversely, urgency may arise from a bladder that signals the need to empty too readily. Simply measuring prostate volume cannot sort these mechanisms out. 4
Nocturia deserves particular attention. Are you waking because your bladder is full, or waking for another reason and then deciding to urinate? Are you passing small amounts repeatedly, or producing a large volume of urine overnight? Sleep apnea, diabetes, fluid intake, and medication timing can contribute. A three-day record of drinking and urination can help distinguish these patterns. 5
The International Prostate Symptom Score, or IPSS, asks seven questions about urinary symptoms. Its symptom total runs from 0 to 35: 0 is asymptomatic, 1–7 mild, 8–19 moderate, and 20–35 severe. A separate question asks how the symptoms affect quality of life. Despite its name, this questionnaire measures symptoms; it does not establish that the prostate caused them. 4
Why did testosterone raise concerns in the first place?
The prostate is androgen-dependent. Within prostate tissue, the enzyme 5-alpha-reductase converts testosterone into dihydrotestosterone, usually shortened to DHT. DHT activates androgen receptors, proteins that influence the expression of genes involved in prostate function and growth. Drugs such as finasteride and dutasteride block this conversion and can reduce prostate volume in appropriately selected men. The androgen pathway is therefore clinically relevant. 1,5
The mistake is assuming that a change in testosterone measured in blood produces a proportional change in androgen activity inside the prostate, followed by a proportional change in urinary symptoms.
In a small randomized trial published in 2006, Marks and colleagues studied 44 men for six months. Testosterone treatment raised circulating testosterone into the normal range without a significant increase in measured prostate-tissue testosterone or DHT. This supports a distinction between hormone concentration in blood and hormone exposure within the gland. It was a short, small mechanistic study, however, not a lifetime safety trial. 6
You may hear this discussed as the androgen saturation model: prostate responses may become less sensitive to further androgen increases once sufficient receptor stimulation is present. It is a model that helps explain why effects need not be linear. It is not a universal safe testosterone threshold, a reason to disregard a rising PSA, or permission to extrapolate replacement-dose findings to anabolic steroid use. 1,6
There are also possible androgen effects on bladder tissue, local inflammation, and signaling pathways that influence smooth muscle relaxation. Much of the mechanistic work comes from laboratory or animal experiments. These findings can suggest why symptoms might remain stable or improve; they cannot establish a clinical treatment benefit by themselves. 1
Urinary symptoms, prostate volume, and prostate safety are distinct outcomes. Original ManMedicine educational graphic, informed by Kathrins 2016, Yuan 2024, and Bhasin 2023. 1,2,3
What did the studies actually find?
The reviews are reassuring about average symptoms, with important gaps
Kathrins and colleagues reviewed 35 prospective trials in a paper published in 2016. Most found no significant prostate growth, and studies involving men with mild baseline symptoms generally found stability or improvement. But 46% of the included trials excluded men with severe symptoms or other indicators of obstruction. Detailed studies of bladder pressure and flow were also scarce. 1
The result is more informative for a man with mild symptoms than for someone who already struggles to empty his bladder. The review also included uncontrolled studies. When men improve during treatment without a comparable untreated group, improvement may reflect other treatment, changes in health, or ordinary fluctuation rather than testosterone itself.
A separate 2016 meta-analysis by Kohn and colleagues combined 14 randomized trials involving 2,029 participants and found no significant difference in IPSS change between testosterone and placebo. This strengthens the argument against routine symptom worsening, while retaining the limitations of the populations and treatment periods studied. 7
Yuan and colleagues extended the question in 2024, comparing administration routes in 21 randomized trials involving 2,453 participants. Overall, the analysis did not find significant IPSS differences between testosterone and placebo by route, or between routes in its network comparisons. 2
There were nuances. A subgroup receiving longer-term intramuscular treatment had an improvement in IPSS. Shorter-term intramuscular treatment showed increased prostate volume, and shorter-term transdermal treatment increased PSA. These findings illustrate why symptom scores, prostate size, and PSA should remain separate outcomes. 2
The paper also ranked intramuscular testosterone favorably for symptom improvement. A statistical ranking is not proof that injections are clinically superior, particularly when direct or indirect comparisons do not demonstrate a significant difference. It is not a reason to choose injections as a BPH treatment. The available abstract does not provide the effect sizes and confidence intervals needed to judge the clinical importance of each subgroup result. 2
TRAVERSE added larger randomized safety data
The 2023 TRAVERSE prostate-safety analysis included 5,204 men, aged 45–80, with symptomatic testosterone deficiency and cardiovascular disease or elevated cardiovascular risk. It compared testosterone gel with placebo. Mean follow-up was 33 months; average treatment exposure was approximately 22 months. Men with an IPSS above 19, a history of prostate cancer, suspicious prostate findings, or a PSA above the trial's eligibility threshold were excluded. 3
IPSS changes did not differ significantly. Adjudicated acute urinary retention occurred in 20 testosterone-treated men versus 16 receiving placebo. Invasive prostate procedures occurred in 23 versus 12; that difference was not statistically significant, but its hazard ratio was 1.91, with a 95% confidence interval of 0.95–3.84. A hazard ratio compares event rates over follow-up; 1 represents no difference. The confidence interval describes the uncertainty around that comparison and includes both no difference and a substantial increase. “Not statistically significant” therefore does not mean that the risks were proven identical. 3
PSA increased more with testosterone. High-grade prostate cancers were uncommon, five versus three, leaving substantial uncertainty around that rare outcome. These results support measured reassurance over the period studied in screened men. They do not settle long-term cancer risk or answer the severe-LUTS question. 3
Some newer evidence points in a less reassuring direction
A claims-database study published in the 2025 issue of Urology, available online in 2024, examined 882,570 men with a hypogonadism diagnosis. Testosterone use was associated with more BPH diagnoses from 2.5 years after the hypogonadism diagnosis onward: hazard ratio 1.32, 95% confidence interval 1.28–1.36. The study did not find a statistically significant difference in BPH interventions. 8
This is a reason to keep longer-term surveillance, not proof that testosterone caused a 32% increase in urinary symptoms. A coded diagnosis is not an IPSS measurement, and an observational comparison can retain differences in surveillance and patient characteristics despite statistical adjustment. It also cannot simply be dismissed because randomized trials were reassuring. The studies ask related but different questions. 8
Could testosterone actually improve urinary symptoms?
Possibly in some men, but the evidence does not justify prescribing it for that purpose.
Some observational studies report improvement, particularly in men with metabolic syndrome, a cluster of problems involving abdominal adiposity, blood pressure, glucose regulation, and blood lipids. Changes in inflammation or overall health may influence urinary function, but the contribution of testosterone is difficult to isolate. 1
A useful test of this idea came from a 2022 placebo-controlled trial in men with metabolic syndrome awaiting BPH surgery. Among the 72 testosterone-deficient men who continued with study procedures, 34 received testosterone and 38 placebo for 24 weeks. Testosterone improved several measures of prostate inflammation, but it did not produce a significant advantage in urinary symptom improvement. Prostate volume was also slightly greater with treatment. 9
A favorable tissue response therefore did not translate into a demonstrated symptom benefit. This small trial provides information in a more symptomatic clinical setting, but cannot establish long-term safety for all men with severe LUTS.
What should you and your clinician check before starting?
First, establish why testosterone is being considered. Symptoms consistent with testosterone deficiency and repeatedly low morning testosterone measurements are the starting point. A weak stream alone is not an indication for testosterone treatment. 10
Second, document the urinary baseline. What is your IPSS? Which symptom is most disruptive? Have you ever needed a catheter? Does the bladder feel persistently full after urination? Reviewing medications, examining you, and checking urine may reveal another explanation. Depending on the findings, urine-flow testing or measurement of residual urine after voiding can help assess emptying. 4
Third, address severe symptoms before assuming the usual trial results apply. The Endocrine Society recommends against initiating testosterone in men with severe LUTS. The European Association of Urology's 2026 guidance treats an IPSS above 19 as a relative contraindication because evidence is insufficient. The wording differs, but both support evaluation and an individualized plan rather than routine initiation in a poorly emptying or severely symptomatic patient. 10,11
Fourth, agree on follow-up. Reassess urinary symptoms alongside the usual testosterone safety monitoring, including testosterone concentration and hematocrit, the proportion of blood occupied by red cells. Discuss prostate assessment and PSA monitoring according to age, risk, and clinical circumstances. 10,11
PSA is a protein produced by prostate cells, not a diagnosis of cancer. Nevertheless, a new rise needs interpretation. The Endocrine Society recommends urological consultation for a confirmed PSA rise above baseline of more than 1.4 ng/mL during the first year, a confirmed PSA above 4 ng/mL, or an abnormal prostate examination. Baseline PSA, infection, and drugs that lower PSA affect interpretation. Do not dismiss an abnormal result as an expected testosterone effect without assessment. 10,12
If symptoms worsen after treatment, what then?
Report the change. Record when it began, whether the testosterone regimen changed, and whether the problem is urgency, nighttime urine production, or difficulty emptying. Your clinician can review the dose and measured testosterone level while checking for infection, retention, medication effects, or progression of another urinary condition.
A temporal relationship deserves attention, but it does not identify the cause by itself. Conversely, a reassuring average trial result does not invalidate your individual symptoms. BPH and other urinary disorders should receive their own treatment when indicated; raising the testosterone dose is not an established strategy for improving urinary flow. 1,4,10
Seek emergency care if you suddenly cannot pass urine, especially with a painful or swollen lower abdomen. Seek prompt medical care for visible blood in the urine or urinary pain with fever or chills. These findings should not wait for the next routine hormone appointment. 13,14
The practical conclusion
For a man with well-documented testosterone deficiency and mild or moderate urinary symptoms, the evidence does not support automatically withholding testosterone because of an assumed worsening of urination. It supports a baseline assessment, appropriate selection, and follow-up.
For a man with severe symptoms, significant incomplete emptying, an unexplained PSA abnormality, or a prostate-cancer history, the decision needs a more specific assessment. The unresolved question is not whether the prostate responds to hormones. It is how a particular treatment changes a particular man's symptoms and risks over time.
Testosterone replacement may be appropriate while urinary symptoms are managed separately. It should neither be blamed automatically for every new symptom nor offered as a substitute for diagnosing and treating the urinary problem.
Educational information, not an individual diagnosis or treatment plan. Do not change prescribed testosterone or urinary medication without discussing it with your clinician.
References
1. Kathrins M, Doersch K, Nimeh T, et al. The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review. Urology. 2016;88:22–32. doi:10.1016/j.urology.2015.11.006.
2. Yuan X, Xiong X, Xue J. Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta-analysis. Journal of Evidence-Based Medicine. 2024;17(3):490–502. doi:10.1111/jebm.12628.
3. Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open. 2023;6(12):e2348692. Full article. doi:10.1001/jamanetworkopen.2023.48692.
4. European Association of Urology. Management of Non-neurogenic Male LUTS, 2026. Diagnostic evaluation.
5. European Association of Urology. Management of Non-neurogenic Male LUTS, 2026. Disease management.
6. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–2361. doi:10.1001/jama.296.19.2351.
7. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. European Urology. 2016;69(6):1083–1090. doi:10.1016/j.eururo.2016.01.043.
8. Fendereski K, Horns JJ, Dehghanbanadaki H, Watkins CM, Hotaling JM. The Impact of Testosterone Therapy on Benign Prostatic Hyperplasia in Hypogonadal Males. Urology. 2025;196:325–332. Published online November 2024. doi:10.1016/j.urology.2024.11.006. PubMed abstract.
9. Rastrelli G, Cipriani S, Lotti F, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. Journal of Endocrinological Investigation. 2022;45:1413–1425. Full article and DOI.
10. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229. Recommendation summary.
11. European Association of Urology. Sexual and Reproductive Health, 2026. Male hypogonadism.
12. National Institute of Diabetes and Digestive and Kidney Diseases. Prostate Tests.
13. National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts of Urinary Retention.
14. National Institute of Diabetes and Digestive and Kidney Diseases. Prostatitis: Inflammation of the Prostate.
Evidence and guideline links checked October 14, 2026.